{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T02:15:59Z","timestamp":1781576159305,"version":"3.54.5"},"update-to":[{"DOI":"10.1371\/journal.pntd.0010433","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T00:00:00Z","timestamp":1654732800000}}],"reference-count":62,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T00:00:00Z","timestamp":1653609600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U19AI142785"],"award-info":[{"award-number":["U19AI142785"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UC7AI094660"],"award-info":[{"award-number":["UC7AI094660"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Marburg virus (MARV), an Ebola-like virus, remains an eminent threat to public health as demonstrated by its high associated mortality rate (23\u201390%) and recent emergence in West Africa for the first time. Although a recombinant vesicular stomatitis virus (rVSV)-based vaccine (Ervebo) is licensed for Ebola virus disease (EVD), no approved countermeasures exist against MARV. Results from clinical trials indicate Ervebo prevents EVD in 97.5\u2013100% of vaccinees 10 days onwards post-immunization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methodology\/Findings<\/jats:title>\n                    <jats:p>Given the rapid immunogenicity of the Ervebo platform against EVD, we tested whether a similar, but highly attenuated, rVSV-based Vesiculovax vector expressing the glycoprotein (GP) of MARV (rVSV-N4CT1-MARV-GP) could provide swift protection against Marburg virus disease (MVD). Here, groups of cynomolgus monkeys were vaccinated 7, 5, or 3 days before exposure to a lethal dose of MARV (Angola variant). All subjects (100%) immunized one week prior to challenge survived; 80% and 20% of subjects survived when vaccinated 5- and 3-days pre-exposure, respectively. Lethality was associated with higher viral load and sustained innate immunity transcriptional signatures, whereas survival correlated with development of MARV GP-specific antibodies and early expression of predicted NK cell-, B-cell-, and cytotoxic T-cell-type quantities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Conclusions\/Significance<\/jats:title>\n                    <jats:p>These results emphasize the utility of Vesiculovax vaccines for MVD outbreak management. The highly attenuated nature of rVSV-N4CT1 vaccines, which are clinically safe in humans, may be preferable to vaccines based on the same platform as Ervebo (rVSV \u201cdelta G\u201d platform), which in some trial participants induced vaccine-related adverse events in association with viral replication including arthralgia\/arthritis, dermatitis, and cutaneous vasculitis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pntd.0010433","type":"journal-article","created":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T13:41:28Z","timestamp":1653658888000},"page":"e0010433","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":38,"title":["A highly attenuated Vesiculovax vaccine rapidly protects nonhuman primates against lethal Marburg virus challenge"],"prefix":"10.1371","volume":"16","author":[{"given":"Courtney","family":"Woolsey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W.","family":"Cross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krystle N.","family":"Agans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktoriya","family":"Borisevich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Deer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan B.","family":"Geisbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"Gerardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa E.","family":"Latham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karla A.","family":"Fenton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Egan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Eldridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0858-1877","authenticated-orcid":true,"given":"Thomas W.","family":"Geisbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Demetrius","family":"Matassov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,5,27]]},"reference":[{"key":"pntd.0010433.ref001","first-page":"608","volume-title":"Marburg and Ravn Viruses (Filoviridae).","author":"C Woolsey","year":"2021","edition":"4"},{"key":"pntd.0010433.ref002","unstructured":"WHO. 2018 Annual review of diseases prioritized under the Research and Development Blueprint. Geneva, Switzerland. Accessed 09 Dec 2021: https:\/\/www.who.int\/emergencies\/diseases\/2018prioritization-report.pdf. 2018."},{"key":"pntd.0010433.ref003","unstructured":"CDC\/USDA. Federal Select Agent Program: HHS and USDA Select Agents and Toxins 7CFR Part 331, 9 CFR Part 121, and 42 CFR Part 73. Accessed 09 Dec 2021: https:\/\/www.selectagents.gov\/sat\/list.htm?CDC_AA_refVal=https:\/\/www.selectagents.gov\/SelectAgentsandToxinsList.html. 2021."},{"issue":"13","key":"pntd.0010433.ref004","doi-asserted-by":"crossref","first-page":"6497","DOI":"10.1128\/JVI.00069-06","article-title":"Marburgvirus Genomics and Association with a Large Hemorrhagic Fever Outbreak in Angola","volume":"80","author":"JS Towner","year":"2006","journal-title":"Journal of Virology"},{"issue":"8","key":"pntd.0010433.ref005","doi-asserted-by":"crossref","first-page":"e764","DOI":"10.1371\/journal.pone.0000764","article-title":"Marburg Virus Infection Detected in a Common African Bat.","volume":"2","author":"JS Towner","year":"2007","journal-title":"PLoS ONE."},{"issue":"10","key":"pntd.0010433.ref006","doi-asserted-by":"crossref","first-page":"e1002877","DOI":"10.1371\/journal.ppat.1002877","article-title":"Seasonal Pulses of Marburg Virus Circulation in Juvenile Rousettus aegyptiacus Bats Coincide with Periods of Increased Risk of Human Infection","volume":"8","author":"BR Amman","year":"2012","journal-title":"PLoS Pathogens"},{"key":"pntd.0010433.ref007","unstructured":"WHO. Press Release 09 Aug 2021: West Africa\u2019s first-ever case of Marburg virus disease confirmed in Guinea. Accessed 09 Dec 2021: https:\/\/worldhealthorganization.cmail19.com\/t\/ViewEmail\/d\/85906C6ABA3E08E32540EF23F30FEDED\/84D956050C9556035281BC0AA5ABFD98. 2021. Epub 09 Aug 2021."},{"issue":"1","key":"pntd.0010433.ref008","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-14327-8","article-title":"Isolation of Angola-like Marburg virus from Egyptian rousette bats from West Africa","volume":"11","author":"BR Amman","year":"2020","journal-title":"Nature Communications"},{"issue":"12","key":"pntd.0010433.ref009","doi-asserted-by":"crossref","first-page":"e1010078","DOI":"10.1371\/journal.ppat.1010078","article-title":"Current state of Ebola virus vaccines: A snapshot.","volume":"17","author":"C Woolsey","year":"2021","journal-title":"PLOS Pathogens"},{"issue":"1","key":"pntd.0010433.ref010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7001a1","article-title":"Use of Ebola Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020.","volume":"70","author":"MJ Choi","year":"2021","journal-title":"MMWR Recommendations and Reports."},{"key":"pntd.0010433.ref011","unstructured":"WHO. Preliminary results on the efficacy of rVSV-ZEBOV-GP Ebola vaccine using the ring vaccination strategy in the control of an Ebola outbreak in the Democratic Republic of the Congo: an example of integration of research into epidemic response. 10 April 2019 meeting report. Accessed 04 Nov 21. Available from: https:\/\/www.who.int\/csr\/resources\/publications\/ebola\/ebola-ring-vaccination-results-12-april-2019.pdf."},{"issue":"10068","key":"pntd.0010433.ref012","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola \u00c7a Suffit!).","volume":"389","author":"AM Henao-Restrepo","year":"2017","journal-title":"The Lancet"},{"issue":"1","key":"pntd.0010433.ref013","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-59976-3","article-title":"Immune correlates of postexposure vaccine protection against Marburg virus","volume":"10","author":"C Woolsey","year":"2020","journal-title":"Scientific Reports"},{"issue":"suppl_5","key":"pntd.0010433.ref014","doi-asserted-by":"crossref","first-page":"S582","DOI":"10.1093\/infdis\/jiy293","article-title":"Postexposure Efficacy of Recombinant Vesicular Stomatitis Virus Vectors Against High and Low Doses of Marburg Virus Variant Angola in Nonhuman Primates","volume":"218","author":"C Woolsey","year":"2018","journal-title":"The Journal of Infectious Diseases"},{"issue":"7","key":"pntd.0010433.ref015","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.3201\/eid1607.100159","article-title":"Postexposure Treatment of Marburg Virus Infection","volume":"16","author":"TW Geisbert","year":"2010","journal-title":"Emerging Infectious Diseases"},{"issue":"suppl_3","key":"pntd.0010433.ref016","doi-asserted-by":"crossref","first-page":"S1075","DOI":"10.1093\/infdis\/jir349","article-title":"Recombinant Vesicular Stomatitis Virus\u2013Based Vaccines Against Ebola and Marburg Virus Infections","volume":"204","author":"TW Geisbert","year":"2011","journal-title":"The Journal of Infectious Diseases"},{"issue":"3","key":"pntd.0010433.ref017","doi-asserted-by":"crossref","first-page":"e01190","DOI":"10.1128\/JVI.01190-17","article-title":"Single-Dose Trivalent VesiculoVax Vaccine Protects Macaques from Lethal Ebolavirus and Marburgvirus Challenge","volume":"92","author":"D Matassov","year":"2018","journal-title":"Journal of virology"},{"issue":"14","key":"pntd.0010433.ref018","doi-asserted-by":"crossref","first-page":"7296","DOI":"10.1128\/JVI.00561-09","article-title":"Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus","volume":"83","author":"TW Geisbert","year":"2009","journal-title":"Journal of virology"},{"issue":"suppl 2","key":"pntd.0010433.ref019","doi-asserted-by":"crossref","first-page":"S384","DOI":"10.1093\/infdis\/jiv126","article-title":"A Single-Vector, Single-Injection Trivalent Filovirus Vaccine: Proof of Concept Study in Outbred Guinea Pigs.","volume":"212","author":"CE Mire","year":"2015","journal-title":"Journal of Infectious Diseases"},{"issue":"19","key":"pntd.0010433.ref020","doi-asserted-by":"crossref","first-page":"9659","DOI":"10.1128\/JVI.00959-06","article-title":"Cross-Protection against Marburg Virus Strains by Using a Live, Attenuated Recombinant Vaccine","volume":"80","author":"KM Daddario-Dicaprio","year":"2006","journal-title":"Journal of Virology"},{"issue":"9520","key":"pntd.0010433.ref021","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S0140-6736(06)68546-2","article-title":"Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment","volume":"367","author":"KM Daddario-DiCaprio","year":"2006","journal-title":"The Lancet"},{"issue":"suppl 2","key":"pntd.0010433.ref022","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1093\/infdis\/jiv284","article-title":"Considerations in the Use of Nonhuman Primate Models of Ebola Virus and Marburg Virus Infection: Table 1.","volume":"212","author":"TW Geisbert","year":"2015","journal-title":"Journal of Infectious Diseases"},{"issue":"4","key":"pntd.0010433.ref023","doi-asserted-by":"crossref","first-page":"e94355","DOI":"10.1371\/journal.pone.0094355","article-title":"Durability of a Vesicular Stomatitis Virus-Based Marburg Virus Vaccine in Nonhuman Primates.","volume":"9","author":"CE Mire","year":"2014","journal-title":"PLoS ONE"},{"issue":"10","key":"pntd.0010433.ref024","doi-asserted-by":"crossref","first-page":"5140","DOI":"10.1128\/JVI.02021-09","article-title":"Different Potential of C-Type Lectin-Mediated Entry between Marburg Virus Strains","volume":"84","author":"K Matsuno","year":"2010","journal-title":"Journal of Virology"},{"issue":"suppl 2","key":"pntd.0010433.ref025","doi-asserted-by":"crossref","first-page":"S258","DOI":"10.1093\/infdis\/jiv182","article-title":"Comparison of the Pathogenesis of the Angola and Ravn Strains of Marburg Virus in the Outbred Guinea Pig Model","volume":"212","author":"RW Cross","year":"2015","journal-title":"Journal of Infectious Diseases"},{"issue":"Suppl 2","key":"pntd.0010433.ref026","doi-asserted-by":"crossref","first-page":"S372","DOI":"10.1086\/520608","article-title":"Marburg virus Angola infection of rhesus macaques: pathogenesis and treatment with recombinant nematode anticoagulant protein c2","volume":"196","author":"TW Geisbert","year":"2007","journal-title":"J Infect Dis"},{"key":"pntd.0010433.ref027","article-title":"Single Dose of a VSV-Based Vaccine Rapidly Protects Macaques From Marburg Virus Disease.","volume":"12","author":"AJA Marzi","year":"2021","journal-title":"Frontiers in immunology"},{"issue":"10","key":"pntd.0010433.ref028","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/S1473-3099(15)00154-1","article-title":"The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1\/2 trial","volume":"15","author":"A Huttner","year":"2015","journal-title":"The Lancet Infectious Diseases"},{"issue":"17","key":"pntd.0010433.ref029","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1056\/NEJMoa1502924","article-title":"Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe.","volume":"374","author":"ST Agnandji","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"pntd.0010433.ref030","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S1473-3099(19)30614-0","article-title":"Safety and immunogenicity of a highly attenuated rVSVN4CT1-EBOVGP1 Ebola virus vaccine: a randomised, double-blind, placebo-controlled, phase 1 clinical trial","volume":"20","author":"DK Clarke","year":"2020","journal-title":"The Lancet Infectious Diseases"},{"issue":"9","key":"pntd.0010433.ref031","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1128\/jvi.63.9.3569-3578.1989","article-title":"Glycoprotein cytoplasmic domain sequences required for rescue of a vesicular stomatitis virus glycoprotein mutant","volume":"63","author":"MA Whitt","year":"1989","journal-title":"Journal of Virology"},{"issue":"7","key":"pntd.0010433.ref032","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1073\/pnas.95.7.3501","article-title":"Gene rearrangement attenuates expression and lethality of a nonsegmented negative strand RNA virus","volume":"95","author":"GW Wertz","year":"1998","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"5","key":"pntd.0010433.ref033","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.1128\/JVI.73.5.3723-3732.1999","article-title":"Attenuated vesicular stomatitis viruses as vaccine vectors","volume":"73","author":"A Roberts","year":"1999","journal-title":"Journal of virology"},{"issue":"4","key":"pntd.0010433.ref034","doi-asserted-by":"crossref","first-page":"e0151721","DOI":"10.1128\/mBio.01517-21","article-title":"Bundibugyo ebolavirus Survival Is Associated with Early Activation of Adaptive Immunity and Reduced Myeloid-Derived Suppressor Cell Signaling","volume":"12","author":"C Woolsey","year":"2021","journal-title":"mBio"},{"issue":"1","key":"pntd.0010433.ref035","doi-asserted-by":"crossref","first-page":"1.30.1","DOI":"10.1002\/cpbi.5","article-title":"The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analyses.","volume":"54","author":"G Stelzer","year":"2016","journal-title":"Current Protocols in Bioinformatics"},{"issue":"15","key":"pntd.0010433.ref036","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/bioinformatics\/btu170","article-title":"Trimmomatic: a flexible trimmer for Illumina sequence data","volume":"30","author":"AM Bolger","year":"2014","journal-title":"Bioinformatics"},{"issue":"6","key":"pntd.0010433.ref037","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1101\/gr.089532.108","article-title":"ABySS: a parallel assembler for short read sequence data","volume":"19","author":"JT Simpson","year":"2009","journal-title":"Genome Res"},{"issue":"14","key":"pntd.0010433.ref038","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","article-title":"Fast and accurate short read alignment with Burrows-Wheeler transform","volume":"25","author":"H Li","year":"2009","journal-title":"Bioinformatics"},{"issue":"1","key":"pntd.0010433.ref039","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/nbt.1754","article-title":"Integrative genomics viewer","volume":"29","author":"JT Robinson","year":"2011","journal-title":"Nat Biotechnol"},{"issue":"22","key":"pntd.0010433.ref040","doi-asserted-by":"crossref","first-page":"11189","DOI":"10.1093\/nar\/gks918","article-title":"LoFreq: a sequence-quality aware, ultra-sensitive variant caller for uncovering cell-population heterogeneity from high-throughput sequencing datasets","volume":"40","author":"A Wilm","year":"2012","journal-title":"Nucleic Acids Res"},{"issue":"19","key":"pntd.0010433.ref041","doi-asserted-by":"crossref","first-page":"10386","DOI":"10.1128\/JVI.00594-10","article-title":"Vector choice determines immunogenicity and potency of genetic vaccines against Angola Marburg virus in nonhuman primates","volume":"84","author":"TW Geisbert","year":"2010","journal-title":"J Virol"},{"issue":"4","key":"pntd.0010433.ref042","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1093\/infdis\/jiu088","article-title":"Ebola Hemorrhagic Fever: Novel Biomarker Correlates of Clinical Outcome","volume":"210","author":"AK McElroy","year":"2014","journal-title":"Journal of Infectious Diseases"},{"issue":"10","key":"pntd.0010433.ref043","doi-asserted-by":"crossref","first-page":"e837","DOI":"10.1371\/journal.pntd.0000837","article-title":"Human Fatal Zaire Ebola Virus Infection Is Associated with an Aberrant Innate Immunity and with Massive Lymphocyte Apoptosis","volume":"4","author":"N Wauquier","year":"2010","journal-title":"PLoS Neglected Tropical Diseases"},{"issue":"7601","key":"pntd.0010433.ref044","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nature17949","article-title":"Unique human immune signature of Ebola virus disease in Guinea","volume":"533","author":"P Ruibal","year":"2016","journal-title":"Nature"},{"issue":"7","key":"pntd.0010433.ref045","doi-asserted-by":"crossref","first-page":"e1006506","DOI":"10.1371\/journal.ppat.1006506","article-title":"KIR3DL01 upregulation on gut natural killer cells in response to SIV infection of KIR- and MHC class I-defined rhesus macaques","volume":"13","author":"M Ries","year":"2017","journal-title":"PLOS Pathogens"},{"issue":"2","key":"pntd.0010433.ref046","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1365-2567.2005.02147.x","article-title":"Delineation of multiple subpopulations of natural killer cells in rhesus macaques","volume":"115","author":"RL Webster","year":"2005","journal-title":"Immunology"},{"issue":"7","key":"pntd.0010433.ref047","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1473-3099(18)30165-8","article-title":"Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study","volume":"18","author":"A Huttner","year":"2018","journal-title":"The Lancet Infectious Diseases"},{"issue":"7549","key":"pntd.0010433.ref048","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/nature14428","article-title":"Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus","volume":"520","author":"CE Mire","year":"2015","journal-title":"Nature"},{"issue":"suppl 2","key":"pntd.0010433.ref049","doi-asserted-by":"crossref","first-page":"S443","DOI":"10.1093\/infdis\/jiv316","article-title":"Vaccination With a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects Against Challenge With a Lethal Dose of Ebola Virus","volume":"212","author":"D Matassov","year":"2015","journal-title":"Journal of Infectious Diseases"},{"issue":"1","key":"pntd.0010433.ref050","article-title":"Rapid dose-dependent Natural Killer (NK) cell modulation and cytokine responses following human rVSV-ZEBOV Ebolavirus vaccination.","volume":"5","author":"D Pejoski","year":"2020","journal-title":"npj Vaccines"},{"issue":"9","key":"pntd.0010433.ref051","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1016\/j.celrep.2017.08.023","article-title":"Systems Vaccinology Identifies an Early Innate Immune Signature as a Correlate of Antibody Responses to the Ebola Vaccine rVSV-ZEBOV","volume":"20","author":"A Rechtien","year":"2017","journal-title":"Cell Reports"},{"key":"pntd.0010433.ref052","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.smim.2018.07.003","article-title":"Correlates of vaccine-induced protective immunity against Ebola virus disease","volume":"39","author":"D Medaglini","year":"2018","journal-title":"Seminars in Immunology"},{"issue":"2","key":"pntd.0010433.ref053","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.virol.2010.12.045","article-title":"Complement and viral pathogenesis","volume":"411","author":"KA Stoermer","year":"2011","journal-title":"Virology"},{"issue":"5","key":"pntd.0010433.ref054","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/j.cell.2020.10.002","article-title":"Single-Cell Profiling of Ebola Virus Disease In Vivo Reveals Viral and Host Dynamics","volume":"183","author":"D Kotliar","year":"2020","journal-title":"Cell"},{"issue":"7","key":"pntd.0010433.ref055","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nri2098","article-title":"How Ebola and Marburg viruses battle the immune system","volume":"7","author":"M Mohamadzadeh","year":"2007","journal-title":"Nature Reviews Immunology"},{"issue":"1","key":"pntd.0010433.ref056","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1089\/vim.2014.0069","article-title":"VSV\u0394G\/EBOV GP-induced innate protection enhances natural killer cell activity to increase survival in a lethal mouse adapted Ebola virus infection","volume":"28","author":"KJ Williams","year":"2015","journal-title":"Viral immunology"},{"issue":"7","key":"pntd.0010433.ref057","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1093\/infdis\/jiz657","article-title":"Antibody-Dependent Natural Killer Cell Activation After Ebola Vaccination","volume":"223","author":"HR Wagstaffe","year":"2021","journal-title":"The Journal of Infectious Diseases"},{"key":"pntd.0010433.ref058","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ebiom.2017.03.045","article-title":"Dose-dependent T-cell Dynamics and Cytokine Cascade Following rVSV-ZEBOV Immunization","volume":"19","author":"C Dahlke","year":"2017","journal-title":"EBioMedicine"},{"issue":"1","key":"pntd.0010433.ref059","doi-asserted-by":"crossref","first-page":"27944","DOI":"10.1038\/srep27944","article-title":"Circulating follicular T helper cells and cytokine profile in humans following vaccination with the rVSV-ZEBOV Ebola vaccine","volume":"6","author":"F Farooq","year":"2016","journal-title":"Scientific Reports"},{"issue":"11","key":"pntd.0010433.ref060","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/nri3536","article-title":"T-bet: a bridge between innate and adaptive immunity","volume":"13","author":"V Lazarevic","year":"2013","journal-title":"Nature Reviews Immunology"},{"issue":"6","key":"pntd.0010433.ref061","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.immuni.2017.05.005","article-title":"The Transcription Factor T-bet Limits Amplification of Type I IFN Transcriptome and Circuitry in T Helper 1","volume":"46","author":"S Iwata","year":"2017","journal-title":"Cells. Immunity"},{"issue":"19","key":"pntd.0010433.ref062","doi-asserted-by":"crossref","first-page":"9865","DOI":"10.1128\/JVI.01142-15","article-title":"Transcriptional Profiling of the Immune Response to Marburg Virus Infection","volume":"89","author":"JH Connor","year":"2015","journal-title":"J Virol"}],"updated-by":[{"DOI":"10.1371\/journal.pntd.0010433","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T00:00:00Z","timestamp":1654732800000}}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0010433","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T13:53:35Z","timestamp":1654782815000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0010433"}},"subtitle":[],"editor":[{"given":"Michael R.","family":"Holbrook","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,5,27]]},"references-count":62,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5,27]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0010433","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.01.22.477345","asserted-by":"object"}]},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,27]]}}}